In 2019, IDL Biotech submitted a so-called Pre-submission request to the US FDA (United States Food and Drug Administration) this was done to ensure the future approval of UBC® Rapid, the companys rapid diagnostic test for bladder cancer. As of now, the company is proceeding with preparations of clinical trial in the United States of America.
Read the press release here
An abstract presented in Tumor Biology (July 2019: 1-74) shows the value of UB® Rapid, for accurate diagnosis and follow-up in bladder cancer. Read the press release here (in swedish)
International Journal of Molecular Sciences has published a study on UBC® Rapid. In total 530 urine samples was included in the multicenterstudy. The author of the study concluded that elevated values of UBC® Rapid Test in urine are higher in patients with...
Bladder cancer is the ninth most commonly diagnosed cancer in the world with an estimated 430 000 new cases reported in 2012. Men are more than three times more likely to get bladder cancer than women. Smoking is a major cause of bladder cancer. Exposure to industrial...
